Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc (NQ: DNLI )

25.38 +0.69 (+2.79%)
Streaming Delayed Price Updated: 11:19 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Denali Therapeutics Inc

< Previous 1 2 3 4 Next >
Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure
Denali Therapeutics is under pressure after the FDA put its study on hold. 
Via Investor's Business Daily
26 Stocks Moving In Thursday's Mid-Day Session
Gainers Dave Inc. (NASDAQ: DAVE) gained 29.4% to $6.73. Takung Art Co., Ltd. (NASDAQ: TKAT) shares gained 18.6% to $4.1499. Traders are circulating earlier news that China is... 
Via Benzinga
Mid-Morning Market Update: Markets Rise; Delta Air Lines Profit Tops Estimates
Following the market opening Thursday, the Dow traded up 0.37% to 36,423.44 while the NASDAQ rose 0.12% to 15,206.73. The S&P also rose, gaining, 0.21% to 4,736.11. The U.S.... 
Via Benzinga
FDA Places Clinical Hold On Denali's Alzheimer's Potential Program
The FDA has issued a clinical hold on Denali Therapeutics Inc's (NASDAQ: DNLI) Investigational New Drug (IND) application for DNL919 (ATV:TREM2). TREM2 is... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares rose 19.8% to $8.18 during Thursday's pre-market session. The market value of their outstanding shares is at $71.4 million. VYNE... 
Via Benzinga
Jim Cramer Says This Stock Is 'Really Cheap'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Academy Sports and Outdoors (NYSE: 
Via Benzinga
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market.... 
Via FinancialNewsMedia
Exposures COVID-19
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program
Denali Therapeutics Inc (NASDAQ: DNLI) announced data from the Phase 1 trial evaluating DNL343, eIF2B activator, in 95 healthy volunteers. DNL343 was generally... 
Via Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
Exposures Product Safety
President And CEO Of Denali Therapeutics Sold $1.00 Million In Stock
Ryan Watts, President and CEO at Denali Therapeutics (NASDAQ:DNLI), made a large insider sell on September 1, according to a new SEC filing. What Happened: A Form 4 filing... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Why Denali Therapeutics Stock Is Sinking Today
The company reported interim results from a phase 1/2 study of its experimental Hunter syndrome drug. 
Via The Motley Fool
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2021
Upgrades According to Compass Point, the prior rating for TriplePoint Venture Growth BDC Corp (NYSE: 
Via Benzinga
48 Stocks Moving In Monday's Mid-Day Session
Gainers Bit Digital, Inc. (NASDAQ: BTBT) gained 38% to $5.83 after the company announced it entered into a second strategic co-mining agreement with Digihost Technology Inc. The... 
Via Benzinga
74 Biggest Movers From Yesterday
Gainers Bit Digital, Inc. (NASDAQ: BTBT) shares jumped 109.7% to close at $8.87 on Monday after the company announced it entered into a second strategic co-mining agreement with... 
Via Benzinga
Denali Therapeutics Stock Crashes; Why Investors Are Questioning Its Entire Pipeline
Denali unveiled promising test results in Hunter syndrome, but DNLI stock tanked Monday on broader pipeline viability questions. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Dynatronics (NASDAQ:DYNT) shares moved upwards by 40.31% to $1.81 during Monday's pre-market session. The company's market cap stands at $31.4 million.... 
Via Benzinga
Denali's Brain-Penetrant Enzyme Therapy Shows Durable Effect With CNS Impact In Hunter Syndrome
Denali Therapeutics Inc (NASDAQ: DNLI) announced additional interim data from a Phase 1/2 study evaluating ETV:IDS (DNL310) for the central nervous system (CNS)... 
Via Benzinga
Tuesday Talk: Action!
U.S. stock markets started the week in continued action mode. The S&P 500 closed at 4,255, up nearly 8 points, the Dow closed at 34,394, down 85 points and the Nasdaq Composite closed at 14,174, up... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021
Upgrades Janney Montgomery Scott upgraded the previous rating for Centerspace (NYSE:CSR) from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $0.95,... 
Via Benzinga
Biden's Budget May Boost These 3 Biotechs
It signals a big push toward curing a neurological disease with a massive market. 
Via The Motley Fool
Exposures COVID-19
Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End
Denali Therapeutics Inc (NASDAQ: DNLI) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.